相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD)
Jai Woo Lee et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2022)
Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor
Rong Hu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
DYRK1A inhibitors for disease therapy: Current status and perspectives
Tong Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE
Sandra N. Craig et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer
Chune Yu et al.
ONCOGENE (2022)
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
Tingting Jiang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
Xiaosa Chang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Non-mitotic functions of polo-like kinases in cancer cells
Christopher A. Raab et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis
Lilia Gheghiani et al.
CANCER RESEARCH (2021)
Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial
Koichi Takahashi et al.
BLOOD (2021)
Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer
Qamraa H. Al-Qahtani et al.
MOLECULAR ONCOLOGY (2021)
CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer
Zhang Yang et al.
CANCER RESEARCH (2021)
PLK1 regulates centrosome migration and spindle dynamics in male mouse meiosis
Enrique Alfaro et al.
EMBO REPORTS (2021)
Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
Pan Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer
Zhaoliang Yu et al.
ADVANCED SCIENCE (2021)
Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies
Zheng Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery
Junping Pei et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a Cut and Glue Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors
Mehmet Karatas et al.
MOLECULES (2021)
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells
Danda Chapagai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Polo-like kinase 1 (Plk1) regulates DNA replication origin firing and interacts with Rif1 in Xenopus
Diletta Ciardo et al.
NUCLEIC ACIDS RESEARCH (2021)
Modulation of KRAS Mutant by Inhibiting PLK1 Kinase in Cancer Therapeutics
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2021)
Co-Targeting Plk1 and DNMT3a in Advanced Prostate Cancer
Zhuangzhuang Zhang et al.
ADVANCED SCIENCE (2021)
Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocycles
David Hymel et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2021)
Polo-like kinase 1 (Plk1) regulates DNA replication origin firing and interacts with Rif1 in Xenopus
Diletta Ciardo et al.
NUCLEIC ACIDS RESEARCH (2021)
Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells
Xupeng Mu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Targeting autophagy-related protein kinases for potential therapeutic purpose
Honggang Xiang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Dual-target kinase drug design: Current strategies and future directions in cancer therapy
Dejuan Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation.
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
David Johnson Einstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors
Natalie Timme et al.
TRANSLATIONAL ONCOLOGY (2020)
Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor
Merissa Baxter et al.
CHEMMEDCHEM (2020)
Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors
Ning-Yu Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Developing polo-like kinase 1 inhibitors
Xufeng Huang et al.
FUTURE MEDICINAL CHEMISTRY (2020)
Discovery of Targeted Covalent Natural Products against PLK1 by Herb-Based Screening
Hao Liang et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)
Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality
Ying Xu et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma
Zhou Deng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Polo-like kinase 1 (Plk1) is a positive regulator of DNA replication in theXenopus in vitrosystem
Diletta Ciardo et al.
CELL CYCLE (2020)
Targeting cell cycle by β-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer
Imad Ahmad et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2020)
Molecular mechanisms of thalidomide and its derivatives
Takumi Ito et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2020)
Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer
Lilia Gheghiani et al.
SCIENTIFIC REPORTS (2020)
The CINs of Polo-Like Kinase 1 in Cancer
Chelsea E. Cunningham et al.
CANCERS (2020)
Oxidative phosphorylation (OXPHOS) dependency predicts response to the Polo-like kinase 1 (PLK1) inhibitor onvansertib in a phase 1b/2 of relapsed/refractory acute myeloid leukemia (R/R AML)
Peter J. P. Croucher et al.
CANCER RESEARCH (2020)
Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1
Celeste N. Alverez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models
Pethaiah Gunasekaran et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells
Zhiheng Li et al.
JOURNAL OF CANCER (2020)
Clinical applications of exosome membrane proteins
Qian Hu et al.
PRECISION CLINICAL MEDICINE (2020)
7-O -Methylwogonin from Scutellaria baicalensis Disturbs Mitotic Progression by Inhibiting Plk1 Activity in Hep3B Cells
Sang-Uk Woo et al.
PLANTA MEDICA (2019)
DITMD-induced mitotic defects and apoptosis in tumor cells by blocking the polo-box domain-dependent functions of polo-like kinase 1
Ka-Ul Kim et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity
Ellen Watts et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors
Xue Zhi Zhao et al.
MOLECULES (2019)
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial
Zachary W. Veitch et al.
BRITISH JOURNAL OF CANCER (2019)
Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
Angela Flavia Serpico et al.
CANCERS (2019)
1066OPolo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory acute myeloid leukaemia in phase Ib
A Zeidan et al.
ANNALS OF ONCOLOGY (2019)
The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults
Anna Jonasova et al.
BLOOD (2019)
A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas
Susanne A. Gatz et al.
FRONTIERS IN ONCOLOGY (2019)
Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold
Xiao Lv et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma
Imane El Dika et al.
ONCOLOGIST (2019)
A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening
Sara Abdelfatah et al.
JOURNAL OF ADVANCED RESEARCH (2019)
Poloxin-2HT+: changing the hydrophobic tag of Poloxin-2HT increases Plk1 degradation and apoptosis induction in tumor cells
Stefan Rubner et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2019)
Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer
Sol-Bi Shin et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
PROTACs: great opportunities for academia and industry
Xiuyun Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis
Jianling Xie et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds
Monika Raab et al.
ACS CHEMICAL BIOLOGY (2018)
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Anand Shah et al.
CLINICAL CANCER RESEARCH (2018)
Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy
Zhaoping Pan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer
Fengyi Mao et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Exploring the structural origins of cryptic sites on proteins
Dmitri Beglov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors
Shuai Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Helicobacter pylori promotes gastric epithelial cell survival through the PLK1/PI3K/Akt pathway
Wenting Xu et al.
ONCOTARGETS AND THERAPY (2018)
Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain
Stefan Rubner et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Trachyspic acid 19-butyl ester, a new inhibitor of Plk1 polo box domain-dependent recognition from uncharacterized fungus RKGS-F2684
Toshihiko Nogawa et al.
JOURNAL OF ANTIBIOTICS (2017)
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors
Jin-Yi Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
An open-label, phase II study of the polo-like kinase-1 (P1k-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
Mark M. Awad et al.
LUNG CANCER (2017)
Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation
Yan-Fang Tao et al.
ONCOLOGY REPORTS (2017)
PLK1, A Potential Target for Cancer Therapy
Zhixian Liu et al.
TRANSLATIONAL ONCOLOGY (2017)
Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway
Xiaoyu Ma et al.
NATURE COMMUNICATIONS (2017)
PLK1 Activation in Late G2 Sets Up Commitment to Mitosis
Lilia Gheghiani et al.
CELL REPORTS (2017)
PLK1-Targeted Fluorescent Tumor Imaging with High Signal-to-Background Ratio
Ji-Ting Hou et al.
ACS SENSORS (2017)
PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy
Stefanie Ruf et al.
AUTOPHAGY (2017)
Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1
Juan Sun et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity
Gabriela Wright et al.
ACS CHEMICAL BIOLOGY (2017)
Gene regulation with carbon-based siRNA conjugates for cancer therapy
Lingmin Zhang et al.
BIOMATERIALS (2016)
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Sai Krishna Athuluri-Divakar et al.
CELL (2016)
Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia
S. Moureau et al.
EUROPEAN JOURNAL OF CANCER (2016)
Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors
Taikangxiang Yun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel
Yi-Sheng Chou et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells
Tan Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Polo kinase Cdc5 associates with centromeres to facilitate the removal of centromeric cohesin during mitosis
Prashant K. Mishra et al.
MOLECULAR BIOLOGY OF THE CELL (2016)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1
Yonghuan Ma et al.
ONCOLOGY REPORTS (2016)
Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration
Fuqin Fan et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling
Jianguo Wu et al.
ELIFE (2016)
Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells
Andrej Scharow et al.
ACS CHEMICAL BIOLOGY (2015)
Development of small molecules targeting the pseudokinase Her3
Sang Min Lim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma
Angelika Stehle et al.
CANCER LETTERS (2015)
Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain
Jung-Eun Park et al.
CELL CYCLE (2015)
Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs
M. Hugle et al.
CELL DEATH AND DIFFERENTIATION (2015)
Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells
Na-Na Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer
Jie Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Allosteric small-molecule kinase inhibitors
Peng Wu et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy
Kyung S. Lee et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer
Neil E. Bhola et al.
CANCER RESEARCH (2015)
Regulation of polo-like kinase 1 by DNA damage and PP2A/B55α
Ling Wang et al.
CELL CYCLE (2015)
A New Class of Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1
Mija Ahn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
Stuart W. J. Ember et al.
ACS CHEMICAL BIOLOGY (2014)
Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer
Zhe Zhang et al.
CANCER RESEARCH (2014)
Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors
Juan Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance
Valeria Sero et al.
INVESTIGATIONAL NEW DRUGS (2014)
Bora and Aurora-A continue to activate Plk1 in mitosis
Wytse Bruinsma et al.
JOURNAL OF CELL SCIENCE (2014)
Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State
Zhiguo Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
The Cep192-Organized Aurora A-Plk1 Cascade Is Essential for Centrosome Cycle and Bipolar Spindle Assembly
Vladimir Joukov et al.
MOLECULAR CELL (2014)
Sequential Cdk1 and Plk1 phosphorylation of caspase-8 triggers apoptotic cell death during mitosis
Yves Matthess et al.
MOLECULAR ONCOLOGY (2014)
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Pietro Ciceri et al.
NATURE CHEMICAL BIOLOGY (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Polo-like kinases: structural variations lead to multiple functions
Sihem Zitouni et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Design and Synthesis of a Cell-Permeable, Drug-Like Small Molecule Inhibitor Targeting the Polo-Box Domain of Polo-Like Kinase 1
Ganipisetti Srinivasrao et al.
PLOS ONE (2014)
The condensin component NCAPG2 regulates microtubule-kinetochore attachment through recruitment of Polo-like kinase 1 to kinetochores
Jae Hyeong Kim et al.
NATURE COMMUNICATIONS (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
Molecular dynamics of PLK1 during mitosis
Stephane Schmucker et al.
MOLECULAR & CELLULAR ONCOLOGY (2014)
Thymoquinone Blocks pSer/pThr Recognition by Plk1 Polo-Box Domain As a Phosohate Mimic
Zhou Yin et al.
ACS CHEMICAL BIOLOGY (2013)
Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features
Zhizhou Fang et al.
ACS CHEMICAL BIOLOGY (2013)
Synthesis and anticancer activity of acyl thioureas bearing pyrazole moiety
Irfan Koca et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Plk1: unexpected roles in DNA replication
Ranadip Mandal et al.
CELL RESEARCH (2013)
A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-Small-Cell Lung Cancer
Peter M. Ellis et al.
CLINICAL LUNG CANCER (2013)
Structural basis for the inhibition of Polo-like kinase 1
Jun Xu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
Alessia Casolaro et al.
PLOS ONE (2013)
Diversity evolution and jump of Polo-like kinase 1 inhibitors
Liao Chenzhong et al.
SCIENCE CHINA-CHEMISTRY (2013)
PI 3-kinase-dependent phosphorylation of Plk1-Ser99 promotes association with 14-3-3γ and is required for metaphase-anaphase transition
Kousuke Kasahara et al.
NATURE COMMUNICATIONS (2013)
PDK1 Signaling Toward PLK1-MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy
Jing Tan et al.
CANCER DISCOVERY (2013)
Identification of High Affinity Polo-like Kinase 1 (Plk1) Polo-box Domain Binding Peptides Using Oxime-Based Diversification
Fa Liu et al.
ACS CHEMICAL BIOLOGY (2012)
Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1a
Dennis L. Buckley et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Identification of novel, potent and selective inhibitors of Polo-like kinase 1
Shaoqing Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
A novel pyrimidine derivatives with aryl urea, thiourea and sulfonamide moieties: Synthesis, anti-inflammatory and antimicrobial evaluation
Ashish P. Keche et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
K. Mross et al.
BRITISH JOURNAL OF CANCER (2012)
Identification of Hydrophobic Tags for the Degradation of Stabilized Proteins
Hyun Seop Tae et al.
CHEMBIOCHEM (2012)
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
Petra Hamerlik et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)
Matthew O. Duffey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens
Yuichi Hikichi et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype
Campbell McInnes et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Natural products as kinase inhibitors
Jing Liu et al.
NATURAL PRODUCT REPORTS (2012)
Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels
Jorg Haupenthal et al.
NEOPLASIA (2012)
Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment
Johan Maertens et al.
BLOOD (2012)
Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors
Marina Caldarelli et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor
Italo Beria et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
From Plk1 to Plk5 Functional evolution of Polo-like kinases
Guillermo de Carcer et al.
CELL CYCLE (2011)
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
David Olmos et al.
CLINICAL CANCER RESEARCH (2011)
Polo-like Kinase 1 Facilitates Loss of Pten Tumor Suppressor-induced Prostate Cancer Formation
X. Shawn Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
PLK1 phosphorylation of pericentrin initiates centrosome maturation at the onset of mitosis
Kwanwoo Lee et al.
JOURNAL OF CELL BIOLOGY (2011)
Benzimidazole Inhibitors Induce a DFG-Out Conformation of Never in Mitosis Gene A-Related Kinase 2 (Nek2) without Binding to the Back Pocket and Reveal a Nonlinear Structure-Activity Relationship
Savade Solanki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Plk1 Phosphorylation of Orc2 Promotes DNA Replication under Conditions of Stress
Bing Song et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel
Fa Liu et al.
NATURE CHEMICAL BIOLOGY (2011)
4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors
Italo Beria et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Biological impact of freezing Plk1 in its inactive conformation in cancer cells
Sarah Keppner et al.
CELL CYCLE (2010)
p53-dependent repression of polo-like kinase-1 (PLK1)
Lynsey McKenzie et al.
CELL CYCLE (2010)
Polo-box domain: a versatile mediator of polo-like kinase function
Jung-Eun Park et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery
X. Shawn Liu et al.
EMBO REPORTS (2010)
Identification of 2-Anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemotypes by Structure-Based Lead Generation
Anne-Marie Egert-Schmidt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Identification of Potent Pyrazolo[4,3-h]quinazoline-3-carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors
Gabriella Traquandi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors
Italo Beria et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
Cell division cycle 6, a mitotic substrate of polo-like kinase 1, regulates chromosomal segregation mediated by cyclin-dependent kinase 1 and separase
Hyungshin Yim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3
Wolfgang Reindl et al.
ANALYTICAL BIOCHEMISTRY (2009)
Identification of a nuclear localization signal in the polo box domain of Plk1
Moon-Sing Lee et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2009)
Discovery of thiophene inhibitors of polo-like kinase
Kyle A. Emmitte et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding
Kyle A. Emmitte et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Identification and Validation of a Potent Type II Inhibitor of Inactive Polo-like Kinase 1
Sarah Keppner et al.
CHEMMEDCHEM (2009)
Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
Maria Gabriella Brasca et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1
Sang-Moon Yun et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin
Tiago M. Bandeiras et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2008)
A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1
Wolfgang Reindl et al.
ANALYTICAL BIOCHEMISTRY (2008)
Itk kinase inhibitors: Initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead
Kevin J. Moriarty et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Inhibition of polo-like kinase 1 by blocking Polo-box domain-dependent protein-protein interactions
Wolfgang Reindl et al.
CHEMISTRY & BIOLOGY (2008)
Plk1 regulates mitotic Aurora A function through βTrCP-dependent degradation of hBora
Eunice H. Y. Chan et al.
CHROMOSOMA (2008)
From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
S. Giordano et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Polo on the rise -: from mitotic entry to cytokinesis with Plk1
Mark Petronczki et al.
DEVELOPMENTAL CELL (2008)
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Libor Macurek et al.
NATURE (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Selectivity-determining residues in Plk1
Michael Kothe et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs
B. Spaenkuch et al.
ONCOGENE (2007)
Structure of the catalytic domain of human polo-like kinase 1
Michael Kothe et al.
BIOCHEMISTRY (2007)
Molecular mechanism of anti-prostate cancer activity of Scutellaria baicalensis extract
Fei Ye et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2007)
5-(1H-benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-ε kinase
Paul Bamborough et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity
Naoki Oshimori et al.
NATURE CELL BIOLOGY (2006)
Tumor inhibition by genomically integrated inducible RNAi-cassettes
Sven Kappel et al.
NUCLEIC ACIDS RESEARCH (2006)
Polo-like kinase 1: Target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis
Frank Eckerdt et al.
CANCER RESEARCH (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
Thymoquinone: A promising anti-cancer drug from natural sources
Hala Gali-Muhtasib et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2006)
Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic Wee1 via multiple pathways
N Watanabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Coordinate regulation of the mother centriole component Nlp by Nek2 and Plk1 protein kinases
J Rapley et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells
C Lindon et al.
JOURNAL OF CELL BIOLOGY (2004)
Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis
MATM van Vugt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Polo-like kinase I is overexpressed in prostate cancer and linked to higher tumor grades
W Weichert et al.
PROSTATE (2004)
Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation
K Ando et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Polo-like kinases and the orchestration of cell division
FA Barr et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex
KY Cheng et al.
EMBO JOURNAL (2003)
The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain
AEH Elia et al.
CELL (2003)
Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates
AEH Elia et al.
SCIENCE (2003)
Nuclear translocation of Plk1 mediated by its bipartite nuclear localization signal
E Taniguchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells
B Spänkuch-Schmitt et al.
ONCOGENE (2002)
Polo-like kinase-1 is a target of the DNA damage checkpoint
VAJ Smits et al.
NATURE CELL BIOLOGY (2000)
分享论文
